Albireo to Present at Investor Conferences in September

BOSTON, Sept. 19, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences in September:

Ladenburg Thalmann Healthcare Conference
Location: Sofitel New York in New York City
Presentation date / time: Tuesday, September 26, 2017 at 9:00 a.m. ET

Cantor Fitzgerald Global Healthcare Conference
Location: InterContinental New York Barclay in New York City
Presentation date / time: Wednesday, September 27, 2017 at 3:25 p.m. ET

A live audio webcast of each presentation will be accessible from the Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to either webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of each webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.

About Albireo 
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Source: Albireo Pharma, Inc.

Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
[email protected]